$CTXR

aTyr (LIFE) appointed Brandon Yaras as CFO. City Therapeutics, Cue Biopharma (CUE), Longeveron (LGVN), Olema Oncology (OLEM), and Stuart Therapeutics made CFO appointments. Sanofi (SNY) expanded its CFO's role to include business operations and M&A.

Citius Pharmaceuticals (CTXR) reported fiscal Q3 2026 results for the quarter ended June 30, 2026. It said nine-month revenue was $7.1 million, driven by LYMPHIR sales, and cash was $17 million. LYMPHIR, FDA-approved in Aug 2024, was available at 44 centers by quarter end. Citius Oncology (CTOR) updated team expansion and Phase 1 data.

Citius Pharmaceuticals reported LYMPHIR (denileukin diftitox-cxdl) revenue of $7.1M for the first nine months of fiscal 2026 and 77% gross margin. Company data presented at ASTCT/CIBMTR showed 86% ORR and 57% CR in a Phase 1 CAR-T combination setting. ASCO investigator data in gynecologic malignancies showed 24% ORR. Cash was $17.0M at June 30, 2026.

Citius Pharmaceuticals (Nasdaq: CTXR) reported fiscal Q3 2026 results for the quarter ended June 30, 2026, and updated on LYMPHIR. Revenues were $1.5M for the quarter and $7.1M for nine months. Cash was $17.0M. LYMPHIR was available at 44 institutions, with expanded Citius Oncology teams and Phase 1 data presented. Citius Oncology (Nasdaq: CTOR) also reported progress and financing.

Citius Pharmaceuticals, Inc. (CTXR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update $7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ® $17 million in cash and cash equivalents as of June 30, 2

H.C. Wainwright began coverage of Citius Pharmaceuticals (CTXR) on May 18 with a Buy rating and $4 price target, citing LYMPHIR’s approval for relapsed/refractory Stage I-III cutaneous T-cell lymphoma and encouraging early launch metrics. The report notes near-full commercial insurance coverage and initial Europe shipments via a regional partner. CTXR’s U.S. launch began in Dec. 2025.

Citius Pharmaceuticals (NASDAQ:CTXR) held its 2026 annual meeting where shareholders elected seven members to its board of directors for a one-year term. The company's shareholders also ratified Wolf & Company, P.C. as their independent registered public accounting firm for the fiscal year ending September 30, 2026. The information was based on an SEC filing.

Citius Pharmaceuticals reported strong early commercial momentum for LYMPHIR, demonstrating rapid institutional adoption with 83% of target accounts reviewing the product and broad payer coverage secured for approximately 80% of lives. The company is seeing sequential growth in orders and no reported reimbursement denials, while continuing its commercial buildout efforts.

Citius Oncology, a subsidiary of Citius Pharmaceuticals (CTXR), reported positive early commercial progress for LYMPHIR, a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL), estimating an initial market exceeding $400 million. The company highlighted growing formulary adoption in oncology centers, expanding payer coverage, and repeat orders, alongside advancing clinical development through academic collaborations for other lymphoma and solid tumors. Key safety concerns for LYMPHIR include capillary leak syndrome, infusion-related reactions, hepatotoxicity, visual impairment, and embryo-fetal toxicity.

Analysts are predicting that Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) will reach breakeven by 2027, transitioning from a projected loss in 2026 to positive profits of US$78m. This forecast implies an optimistic year-on-year growth rate of 48%. The company's low debt-to-equity ratio of 1.3% is highlighted as a positive financial management indicator.